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AML  Acute Myeloproliferative Leukaemia 
ASM  Aggressive Systemic Mastocytosis 
b2M  Beta 2 Microglobulin 
BM  Bone Marrow 
BSA  Bovine Serum Albumin  
CM  Cutaneous Mastocytosis 
CRP  C-Reactive Protein 
CXCL7  Platelet basic protein 
DAVID  Database Annotation Visualisation and Integrated Discovery 
DCM  Diffused Cutaneous Mastocytosis 
DDA  Data Dependant Acquisition 
DIA  Data Independent Acquisition 
DOC  Sodium Deoxycholate  
DTT  Dithiothreitol 
FDA  Food and Drink Administration 
FDR  False Discovery Rate  
GO  Gene Ontology 
IAA  Iodoacetamide 
IL  Interleukin 
IM  Imatinib Mesylate 
INFa  Interferon alpha 
IRTs  Indexed Retention Times  
ISM  Indolent Systemic Mastocytosis 
LBP  Liposaccharide Binding Protein 
MCL  Mast Cell Leukaemia  
MCS  Mast Cell Sarcoma  
MDS  Myelodysplastic Syndromes  
MPCM  Maculopapular Cutaneous Mastocytosis 
MS  Mass Spectrometry  
PANTHER Protein Annotation Through Evolutionary Relationships  
PCA  Principle Component Analysis 
PD-1  Programmed cell death protein 1 
PD-L1  Programmed cell death protein 1 Ligand  
PDGFrb Platelet derived growth factor receptor beta 
PPI  Protein-protein Interactions  
SCF  Stem Cell Factor 
SM  Systemic Mastocytosis  
SM-AHN Systemic Mastocytosis with associated Haematological neoplasm  
SSM  Smouldering Systemic Mastocytosis 
SWATH-MS Sequential Window Acquisition of all Theoretical Mass Spectrometry 
TGFb1  Transforming Growth Factor Beta 1 
WHO  World Health Organisation 




















































































































































































































































































































































































































• Indolent SM <10%
• Smouldering SM <10%
• SM with	AHN 1%
• Aggressive	SM 5%










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































669	 28	 11.22	 +	 2.49	 2.26E-05	
immune	response		 383	 22	 6.43	 +	 3.42	 1.18E-06	
endocytosis		 378	 21	 6.34	 +	 3.31	 3.40E-06	








94	 13	 1.58	 +	 8.24	 2.42E-08	








144	 13	 2.42	 +	 5.38	 2.16E-06	




57	 5	 0.96	 +	 5.23	 3.56E-03	












20	 2	 0.34	 +	 5.96	 5.05E-02	





























38	 47	 13.15	 +	 3.57	 1.57E-13	
VEGFA-VEGFR2	Pathway		
	
43	 21	 5.13	 +	 4.09	 1.35E-07	
Signaling	by	FGFR2		
	




15	 19	 4.6	 +	 4.13	 4.65E-07	
Signaling	by	SCF-KIT		
	




19	 15	 6.19	 +	 2.42	 1.91E-03	
Platelet	degranulation			
	
74	 14	 2.1	 +	 6.68	 7.81E-08	
TCR	signaling		
	








122	 11	 0.87	 +	 12.61	 6.04E-09	
Complement	cascade		
	




















346	 3	 0.25	 +	 11.92	 3.02E-03	
Regulation	of	TLR	by	
endogenous	ligand		












































































































































































































































































































































































































































































































































most	 abundant	 peptides	 are	 the	 ones	 selected	 based	 on	 having	 a	 much	 higher	
concentration	 in	 the	 sample,	meaning	 it	 is	 difficult	 to	 reproducibly	 quantify	 and	
identify	the	lowest	abundance	peptides	in	the	sample	(Kang	et	al	2017).		
In	 contrast,	 when	 utilising	 DIA	 all	 the	 peptides	 identified	 are	 subjected	 to	
fragmentation	 without	 being	 predefined	 enabling	 improved	 accuracy	 in	 peptide	
quantification	and	profiling.	




and	 reduced	 error	 rate	 when	 compared	 with	 DDA.	 Only	 the	 DIA	 approach	
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Quantitative Proteomic Studies in Mastocytosis
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Abstract Content: Mastocytosis is a myeloproliferative disease that is characterised by the accumulation of neoplastic mast cells in
one or several organs resulting in mediator release symptoms, tissue damage and, in aggressive cases, organ failure. The vast majority
of adult patients with mastocytosis present with systemic mastocytosis (SM) and it is defined as mast cell accumulation in one or
more visceral organs. Despite advances in the understanding of myeloid neoplasia the aetiology of mastocytosis is poorly understood.
Around 80-90% of patients with SM harbour a somatic activating mutation in the c-KIT gene (D816V). The D816V mutation results
in the constitutive activation of the c-Kit receptor causing the activation of multiple signalling pathways resulting in an increased
proliferative and survival advantage of the mast cell lineage. However, the presence of the c-KIT mutation does not explain the
heterogeneous clinical behaviour of the disease, and the molecular mechanisms underlying the different subtypes of SM remain
largely elusive.There is a clear need to develop strategies that will aid in the understanding of the molecular pathology of SM.  We
carried-out a global discovery proteome analysis of the plasma of SM patients (n=3) and compared these to healthy control plasma
samples(n=3); using the new high resolution mass spectrometry protocol Sequential Window Acquisition of all Theoretical fragment-
ion spectra mass spectrometry (SWATH MS). SM patients were chosen for eligibility using the WHO selection criteria. Samples
were immunodepleted and SWATH MS permanent digital proteomic maps were generated for all samples on an 6600 TripleTOF
mass spectrometer (AB Sciex, Warrington, UK) and an Eksigent 1D+ Nano LC systems (Eksigent, Dublin, CA) all samples were run
with triplicate mass spectrometry injections per sample. We identified ~1000 proteins in each of the samples at a 5% FDR and they
were mapped on to their relevant pathways using KEGG. Heatmaps and volcano plots were generated using the MSstats program in
the R environment. Bioinformatic analysis and pathway mapping demonstrated that a number of immunological and metabolic
pathways were significantly upregulated in the plasma of the mastocytosis patients including B cell proliferation, phagocytosis
response and calcium signalling. Full characterisation of key regulatory pathways in relation to mastocytosis disease aetiology will
identify new direct cellular targets potentially paving the way for new bespoke treatment strategies in this blood disorder.
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